

# UCSF

## UC San Francisco Previously Published Works

### Title

KRAS is vulnerable to reversible switch-II pocket engagement in cells

### Permalink

<https://escholarship.org/uc/item/4063p0hw>

### Journal

Nature Chemical Biology, 18(6)

### ISSN

1552-4450

### Authors

Vasta, James D

Peacock, D Matthew

Zheng, Qinheng

et al.

### Publication Date

2022-06-01

### DOI

10.1038/s41589-022-00985-w

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



OPEN

# KRAS is vulnerable to reversible switch-II pocket engagement in cells

James D. Vasta<sup>1,3</sup>, D. Matthew Peacock<sup>1,2,3</sup>, Qinheng Zheng<sup>1,2,3</sup>, Joel A. Walker<sup>1</sup>, Ziyang Zhang<sup>1,2</sup>, Chad A. Zimprich<sup>1</sup>, Morgan R. Thomas<sup>1</sup>, Michael T. Beck<sup>1</sup>, Brock F. Binkowski<sup>1</sup>, Cesear R. Corona<sup>1</sup>, Matthew B. Robers<sup>1</sup>✉ and Kevan M. Shokat<sup>1,2</sup>✉

**Current small-molecule inhibitors of KRAS(G12C) bind irreversibly in the switch-II pocket (SII-P), exploiting the strong nucleophilicity of the acquired cysteine as well as the preponderance of the GDP-bound form of this mutant. Nevertheless, many oncogenic KRAS mutants lack these two features, and it remains unknown whether targeting the SII-P is a practical therapeutic approach for KRAS mutants beyond G12C. Here we use NMR spectroscopy and a cellular KRAS engagement assay to address this question by examining a collection of SII-P ligands from the literature and from our own laboratory. We show that the SII-Ps of many KRAS hotspot (G12, G13, Q61) mutants are accessible using noncovalent ligands, and that this accessibility is not necessarily coupled to the GDP state of KRAS. The results we describe here emphasize the SII-P as a privileged drug-binding site on KRAS and unveil new therapeutic opportunities in RAS-driven cancer.**

The *KRAS* proto-oncogene is the most frequently mutated oncogene in cancer<sup>1</sup>. Glycine 12 mutations are the most common, with *KRAS*(G12D) representing the most common substitution in pancreatic ductal adenocarcinoma and colorectal tumors<sup>1</sup>. *KRAS* proteins had long been considered “undruggable” until the identification of covalent drugs targeting *KRAS*(G12C)<sup>2,3</sup>. The drug sotorasib (AMG510, **1**) was recently approved for treatment of patients with the *KRAS*(G12C) mutation, and six additional drugs targeting this same mutant are currently under clinical investigation<sup>4–6</sup>. Several features to *KRAS*(G12C) enabled this allele to be the first *KRAS* mutant to be drugged. The somatic mutation of glycine 12 to cysteine provided the opportunity to exploit covalent drug-discovery methods that are not applicable to the other common *KRAS* alleles (for example, G12D/G12V/Q61H). Sotorasib and other known irreversible *KRAS*(G12C) drugs bind to the SII-P and only engage the inactive GDP state of *KRAS*(G12C)<sup>2,5–10</sup>. A rare example of a molecule reported to target the active GTP state was recently disclosed that relies on a “molecular glue” mechanism involving the recruitment of cyclophilin not widely applicable to other *KRAS*(G12C) inhibitors<sup>11</sup>. Although the *KRAS*(G12C) protein is insensitive to GTPase activating protein (GAP)-mediated hydrolysis, this allele is unique among the *KRAS* oncogenes in maintaining near wild-type (WT) intrinsic GTPase activity—thereby allowing for successful GDP-state targeting for this allele<sup>12</sup>. To effectively inhibit other oncogenic *KRAS* alleles that do not adequately sample the GDP state in cells, drugs that bind reversibly to the GTP state will probably be required.

Studies using engineered proteins and cyclic peptides to probe the SII-P of *KRAS* have revealed the dynamic nature of this pocket and support the possibility that *KRAS*–GTP may adopt conformations favorable to SII-P engagement<sup>13–17</sup>. However, proteins and most cyclic peptides are impermeable to cell membranes, making them difficult to use as drug leads. The recent flurry of drug discovery aimed at targeting *KRAS* reported in the literature and patent

filings might provide suitable small-molecule leads for reversible *KRAS* inhibition. However, the nucleotide state requirements of these molecules are unknown. Although reporter-based methods to query downstream signaling from *KRAS* have been described<sup>18</sup>, robust methods to directly measure in-cell engagement of noncovalent ligands at *KRAS* are unknown.


In this study, we investigated the reversible binding of *KRAS* small-molecule inhibitors to determine which hotspot mutants are vulnerable to SII-P engagement in cells. We used HSQC NMR spectroscopy to directly observe reversible binding to the SII-P of *KRAS* in vitro and determine the nucleotide state dependency of binding. We developed a bifunctional cell-permeable fluorescent probe from the SI/II pocket inhibitor BI-2852 (**2**), and this probe was utilized in a competitive bioluminescence resonance energy transfer (BRET) format<sup>19–21</sup> to quantify SII-P engagement to multimeric RAS complexes in live cells. These studies represent an observation and quantification of direct target engagement of non-G12C oncogenic *KRAS* mutants in cells by reversible binders. Our results expose a wide scope of vulnerability to SII-P engagement across hotspot mutants and should help guide the development of future inhibitors and therapeutics.

## Results

**Reversible *KRAS* SII-P binding is observed by NMR spectroscopy.** The well-established and clinically validated inhibitors of *KRAS*(G12C) such as ARS-1620 (**3**), AMG510 and MRTX849 (**4**) (Fig. 1a) rely on a covalent reaction with the nucleophilic cysteine 12 in the GDP state. Although these molecules bind the same pocket and are similar chemotypes, MRTX849—and the closely related MRTX1257 (**5**)—possess unique structural elements proposed to increase the reversible component of their binding, resulting in a measurable  $K_i$  of 3.7  $\mu\text{M}$  for the reaction of MRTX849 with *KRAS*(G12C)<sup>7</sup>. We sought to determine whether these molecules also bind RAS proteins lacking the G12C mutation and whether their reversible affinity is specific to the inactive GDP state.

<sup>1</sup>Promega Corporation, Madison, WI, USA. <sup>2</sup>Department of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California San Francisco, San Francisco, CA, USA. <sup>3</sup>These authors contributed equally: J. D. Vasta, D. M. Peacock, Q. Zheng.

✉e-mail: [Matt.Robers@promega.com](mailto:Matt.Robers@promega.com); [Kevan.Shokat@ucsf.edu](mailto:Kevan.Shokat@ucsf.edu)



**Fig. 1 | In vitro noncovalent binding to the KRAS SII-P determined by NMR spectroscopy. a**, Chemical structures of AMG510 (1), MRTX849 (4), MRTX1257 (5) and MRTX-EX185 (6). **b**, Summary of the effects of SII-P binders on  $^1H$ - $^{15}N$  HSQC NMR spectra of RAS proteins. **c**, Examples of CSPs of GDP-loaded KRAS in the presence of MRTX849 and comparison of irreversible binding to KRAS(G12C) and reversible binding to KRAS(G12D). Spectra recorded at pH 7.4 and 298 K with 100  $\mu M$   $U$ - $^{15}N$  protein and 200  $\mu M$  ligand.

Cell-free analysis of binding to RAS proteins was performed via protein-observed NMR spectroscopy (Fig. 1b,c). We expressed uniformly  $^{15}N$ -labeled KRAS 1–169, KRAS(G12C) 1–169, KRAS(G12D) 1–169 and HRAS 1–166 proteins and acquired a series of  $^1H$ - $^{15}N$  HSQC NMR spectra (Supplementary Note 1). The addition of either MRTX849 or MRTX1257 (200  $\mu M$ ) to the GDP-loaded state of either KRAS or KRAS(G12D) protein (100  $\mu M$ ) resulted in the formation of a new complex with strong chemical shift perturbations (CSPs) from the peaks of the unbound protein (Fig. 1b,c and Supplementary Note 1, spectra 2, 3, 6 and 7). The same CSPs were observed in samples containing substoichiometrically ligated proteins (100  $\mu M$  protein and 30  $\mu M$  ligand; Supplementary Note 1, spectrum 25), indicating that these ligands tightly bind the proteins with  $k_{off}$  values smaller than the frequency separation between peaks of bound and unbound proteins (<80 Hz). Although the lack of chemical exchange poses a challenge to assigning most peaks of the protein–ligand complexes to their respective residues, some key residues of the covalent KRAS(G12C)–MRTX849 and the noncovalent KRAS(G12D)–MRTX849

complexes could be reassigned from three-dimensional  $^1H$ - $^{15}N$ - $^1H$  NOESY-HSQC spectra. Similarities in perturbations of these residues (excepting glycine 13) support a similar binding conformation between the noncovalent (G12D) and covalent (G12C) complexes of MRTX849 (Fig. 1c, Supplementary Fig. 1 and Supplementary Note 1, spectra 26 and 27).

By contrast, no effects were observed on the spectra of KRAS or KRAS(G12D) proteins containing the nonhydrolyzable GTP analog GPPNHP (GNP) with 200  $\mu M$  of either MRTX849 or MRTX1257 (Fig. 1b and Supplementary Note 1, spectra 14, 15, 18 and 19). Furthermore, only concentration-dependent peak broadening and weak CSPs were observed from the addition of either molecule to GDP-loaded HRAS 1–166 under the same conditions (Supplementary Note 1, spectra 10 and 11), suggesting only weak occupancy of the HRAS SII-P even at the highest concentration tested (100  $\mu M$  protein and 300  $\mu M$  ligand). The results of these HSQC NMR experiments show that MRTX849 and MRTX1257 bind KRAS proteins with high selectivity for the inactive GDP-loaded state and for the K-isoform over HRAS.

A series of similar  $^1\text{H}$ – $^{15}\text{N}$  HSQC NMR experiments provided some evidence for weak binding of AMG510 (Fig. 1a) to the SII-P of GDP-loaded KRAS and HRAS proteins (Fig. 1b and Supplementary Note 1, spectra 1, 5 and 9). Peaks corresponding to residues in the SII-P broadened and exhibited weak (generally less than line-widths) CSPs in the presence of 200  $\mu\text{M}$  of AMG510. These experiments suggest that the reversible affinity of AMG510 to RAS proteins is probably too weak to be relevant to in-cell experiments conducted at lower concentrations, and that AMG510 must rely on the irreversible reaction at the mutant cysteine 12 for its inhibitory activity, which is consistent with previously published data<sup>5</sup>.

Recently, compounds reported to target KRAS(G12D) were disclosed in patent applications by multiple groups<sup>22–25</sup>. We selected and synthesized an example from Mirati Therapeutics patent filings<sup>25</sup> (MRTX-EX185, **6**) with structural features similar to MRTX849/1257 (Fig. 1a). We found that MRTX-EX185 bound GDP-loaded KRAS and KRAS(G12D) by HSQC NMR spectroscopy (Fig. 1b and Supplementary Note 1, spectra 4, 8 and 28), but in stark contrast to MRTX849/1257, MRTX-EX185 also bound the active GNP state of these proteins (Supplementary Note 1, spectra 16 and 20). Furthermore, MRTX-EX185 also bound GDP-loaded HRAS (Supplementary Note 1, spectrum 12). In each of these five cases, identical CSPs were observed in samples containing either 100  $\mu\text{M}$  protein and 200  $\mu\text{M}$  ligand or containing 100  $\mu\text{M}$  protein and 30  $\mu\text{M}$  ligand (substoichiometric), indicating that the  $k_{\text{off}}$  values for these complexes are small (Supplementary Note 1, spectrum 25). When a substoichiometric amount of ligand (50  $\mu\text{M}$ ) was added to a sample containing both GDP- and GNP-loaded KRAS proteins (100  $\mu\text{M}$  each), the GDP–KRAS–MRTX-EX185 complex formed exclusively, and the same experiment with KRAS(G12D) yielded the same result (Supplementary Fig. 2 and Supplementary Note 1, spectra 29 and 30). These results suggest that the relative affinity of MRTX-EX185 to the GDP state over the GNP state of KRAS proteins is greater than the noise limit of the spectra (more than ten for most peaks).

These cell-free NMR experiments show that MRTX849 and MRTX1257 engage KRAS proteins even in the absence of a nucleophilic mutant cysteine 12. However, this engagement is selective for the inactive GDP-loaded state of the protein. The more recently disclosed MRTX-EX185, by contrast, engages both nucleotide states—albeit with preference for the inactive GDP-loaded protein—and might present an opportunity to inhibit even constitutively active (GTP-loaded) KRAS hotspot mutants. However, these NMR experiments require high concentrations of proteins and do not quantify the potency of these tightly binding compounds. Furthermore, in vitro binding assays may not be representative of the in-cell vulnerability of a regulated, effector-bound and membrane-localized protein such as KRAS.

### Observing reversible KRAS SII-P occupancy in cells with BRET.


With our NMR results supporting the potential of KRAS and its hotspot mutants to be vulnerable to noncovalent SII-P occupancy, we asked whether these SII-P ligands engage KRAS in cells. We first assessed the antiproliferative effects of MRTX849 in a number of G12C and non-G12C KRAS mutant and KRAS WT cell lines (Supplementary Fig. 3a). Although MRTX849 inhibited the growth of SW-1990 (KRAS(G12D)) and HCT-116 (KRAS(G13D)) at micromolar concentrations, it also had the same effect on HEK293 (KRAS WT, RAS-independent)<sup>26</sup> and A375 (BRAF V600E, RAS-independent), suggesting the antiproliferative effects may originate from RAS-independent toxicity (Supplementary Fig. 3a). We also measured the ability of MRTX849 to inhibit extracellular signal-related kinase (ERK) phosphorylation in a similar panel of cell lines (Supplementary Fig. 3b). We corroborated the strong potency of MRTX849 in KRAS(G12C)-driven cell lineages. However, in non-G12C driven cell lineages, the nonspecific cytotoxic

effects were observed over the same concentration range as the inhibitory effects on ERK phosphorylation (Supplementary Fig. 3b), thus preventing a clear confirmation of cellular target engagement.

The interference from off-target toxic effects in these assays precluded the analysis of target engagement and prompted us to develop new approaches to determine ligand–RAS interaction in cells. To more directly query biophysical engagement of KRAS and HRAS with small-molecule target engagement in cells, a BRET reporter system was developed. We synthesized a pan-RAS BRET probe (**7**) by conjugating a fluorophore to a derivative of the reversible SI/II-P inhibitor BI-2852 (ref. 27) (Fig. 2a). Recognizing the multimeric and membrane-localized nature of RAS<sup>28–31</sup>, we sought to generate a BRET signal conditionally within membrane-associated RAS complexes<sup>32</sup>. We configured a luminescent complementation-based system (NanoBiT)<sup>21</sup> that was dependent upon RAS lipidation as the BRET donor (Fig. 2b,c and Supplementary Figs. 4 and 5). Luminescent imaging confirmed the membrane localization of RAS dimers in live cells (Supplementary Fig. 4). Furthermore, homodimeric NanoBiT-RAS was functionally validated using an intracellular CRAF-Ras binding domain (RBD)-HaloTag interaction assay (Supplementary Fig. 5a–d) and was competent to activate phospho-ERK (p-ERK) in cells (Supplementary Fig. 5e). Removal of critical lipidation residues (C185S or removal of the hyper variable region) resulted in a dramatic decrease in luminescence, supporting the need for membrane anchoring for the RAS multimerization (Fig. 2c and Supplementary Fig. 5f). Titration of BI-2852 did not impact the RAS dimerization NanoBiT signal in live cells, supporting that RAS is constitutively oligomerized in this assay system (Supplementary Fig. 5g). When cells expressing the BRET donor complexes were treated with the SI/II-P RAS BRET probe **7**, we observed a strong BRET signal that was readily competed to instrument background by unmodified BI-2852 in cells (Fig. 2d,e and Supplementary Fig. 6). Moreover, BI-2852 had no effect on the BRET or luminescence in an irrelevant target engagement assay (Supplementary Fig. 6l), confirming specificity in the competitive effects observed in the RAS assays. Hill coefficients for BI-2852 across all RAS variants studied ranged from 1.3 to 3.3 with a mean of  $1.9 \pm 0.7$ , consistent with cooperative binding of two BI-2852 molecules to a dimeric RAS, as proposed previously<sup>33</sup>. Competitive engagement results with a *tert*-butyloxycarbonyl-protected precursor to the RAS BRET probe (**8**) indicated that the linker functionalization of the BI-2852 derivative resulted in a decrease in affinity to RAS (Supplementary Fig. 7), but that affinity was still sufficient to yield a strong BRET signal between dimeric RAS species and the RAS BRET probe in live cells.

To determine whether the RAS BRET probe binds with a mechanism similar to that of BI-2852, we introduced a mutation (D54R) that is expected to abolish probe engagement on the basis of structural analysis (Supplementary Fig. 8a). As expected, mutation of D54 to R in KRAS resulted in complete loss of BRET with the RAS BRET probe (Supplementary Fig. 8c) without effecting dimerization (Supplementary Fig. 8b). KRAS(D54R) dimers were still competent to engage CRAF-RBD effectors in cells, as evidenced by its interaction with CRAF-RBD-HaloTag (Supplementary Fig. 8d). Although CRAF-RBD was able to interact with KRAS(D54R) dimers, BI-2852 was unable to inhibit the interaction, further validating this mutation as a negative control (Supplementary Fig. 8d). Overexpression of full-length CRAF also attenuated the BRET observed between KRAS and the RAS BRET probe (Supplementary Fig. 8e), further supporting that the probe binds with a mechanism similar to BI-2852 and is competitive with effector interactions.

To evaluate the sensitivity of the SI/II-P BRET probe to allosteric target engagement within the SII-P, live HEK293 cells expressing NanoBiT–KRAS(G12C) were challenged with SII-P ligands AMG510 or ARS-1620 in the presence of the RAS BRET probe (Fig. 3a). Time- and dose-dependent competition was observed




**Fig. 2 | Target engagement assay for RAS. a**, Chemical structure of SII/II-P RAS BRET probe (7). **b**, Illustration of the RAS cellular target engagement assay. A luminescent complex is formed between RAS multimers in live cells; competitive displacement of the BRET probe reduces BRET signal while leaving the NanoBiT complex intact. Target engagement leads to competitive displacement of the BRET probe at RAS dimers. **c**, Removal of the hyper variable region or mutation at C185S results in a loss of luminescence in HEK293 cells compared with full-length KRAS WT, supporting RAS lipidation signals as critical to assay signal (left). Results are the mean  $\pm$  s.e.m. of three independent experiments ( $n=3$ ). **d**, RAS BRET probe dose response for KRAS WT. BRET fold change is calculated by normalizing the BRET ratio of each point by the BRET ratio in the absence of BRET probe (instrument background). The BRET signal was competed by 20  $\mu\text{M}$  BI-2582 (2), demonstrating specificity. Data are the mean  $\pm$  s.e.m. of three independent experiments ( $n=3$ ). **e**, Live cell target engagement is observed at WT KRAS with BI-2582, but not with AMG510 (1). BRET is normalized relative to a saturating (20  $\mu\text{M}$ ) dose of BI-2582, as marked. RLU stands for relative luminescence units.

between AMG510 or ARS-1620 and the RAS BRET probe (Fig. 3b and Supplementary Fig. 9a,b). Unlike for BI-2582, AMG510 and ARS-1620 produced Hill coefficients closer to unity (0.8 and 1.1, respectively), consistent with a lack in cooperativity in the binding to the SII-P of KRAS(G12C). At a 2h timepoint, BRET results with both AMG510 and ARS-1620 closely matched the potency of endogenous target engagement and p-ERK inhibition at identical timepoints in a number of G12C driven lineages (MIA PaCa-2, NCI-H358), corroborating the accuracy of the BRET method as a proxy for engagement in an endogenous cellular setting (Fig. 3C and Supplementary Fig. 9b). AMG510 demonstrated exquisite engagement selectivity for KRAS(G12C) compared with KRAS WT, other KRAS hotspot mutants, and HRAS WT (Supplementary Fig. 9c), consistent with previous reports for functional selectivity between KRAS(G12C) and non-G12C driven cancer cell lines. Like BI-2582, AMG510 did not impact the luminescence produced by NanoBiT-KRAS(G12C) (Supplementary Fig. 9d). Additional SII-P inhibitors

were evaluated at KRAS(G12C) complexes, including MRTX849 and MRTX1257 (Supplementary Fig. 9e). Each produced BRET target engagement results that agreed closely with published cellular potency at KRAS(G12C) lineages<sup>7</sup>. MRTX849/1257 were the most potent KRAS(G12C) inhibitors in the analysis, in close agreement with previous studies<sup>7</sup>. Together the results for engagement of KRAS(G12C) with SII-P ligands support the potential of the BRET target engagement system to report on KRAS in its endogenous cellular setting, and that this system can be used to accurately query engagement across oncogenic KRAS mutants in live cells.

This BRET target engagement system enabled us to directly assess the engagement of WT KRAS and numerous critical hotspot mutants by SII-P ligands. For example, following 2h incubation, engagement of both MRTX849 and MRTX1257 was observed for WT KRAS complexes in the submicromolar range (half-maximum inhibitory concentration ( $\text{IC}_{50}$ )  $\sim$  600 nM) (Fig. 4a,d, Supplementary Table 1 and Supplementary Fig. 10a). When KRAS hotspot mutants were



**Fig. 3 | Measuring SII-P engagement of KRAS(G12C).** **a**, The SII-P BRET probe is used to quantify binding of unmodified SII-P ligands to RAS in live cells. Image created with BioRender.com from PDB 6OIM (AMG510-KRAS(G12C)). **b**, Protracted KRAS(G12C) engagement is observed for AMG510 (**1**). Data are representative of two independent experiments ( $n=2$ ), and individual data points are the mean  $\pm$  s.d. of four technical replicates. **c**, Comparison of BRET target engagement data after 2 h at KRAS(G12C) versus p-ERK from MIA PaCa-2 cells as reported<sup>5</sup>. Data are means of four independent experiments  $\pm$  s.e.m. ( $n=4$ ).

evaluated, a wide spectrum of engagement was observed (Figs. 4a,b and 5b, Supplementary Table 1 and Supplementary Fig. 10b–g). Although no engagement of MRTX849/1257 was observed for


KRAS G12V and Q61R, modest engagement was observed for the remaining KRAS hotspot mutants in the single-digit micromolar range (IC<sub>50</sub> ranging from 1 to 5  $\mu\text{M}$ ). Among the KRAS hotspot mutants excluding KRAS(G12C), the most potent engagement was observed for G13D, Q61H and Q61L (Supplementary Fig. 10d–f).

WT HRAS as well as two oncogenic HRAS mutants (G12C and G12V) were also evaluated for SII-P vulnerability using the BRET assay. No engagement was observed for WT HRAS with AMG510, MRTX849 or MRTX1257 (Supplementary Figs. 9c and 10h). Although HRAS(G12V) was also not vulnerable to SII-P engagement (Supplementary Fig. 10i), HRAS(G12C) showed vulnerability to both AMG510 and MRTX849 (Supplementary Fig. 10j). AMG510 demonstrated similar intracellular affinity towards HRAS(G12C) compared with KRAS(G12C), but MRTX849 demonstrated affinity for HRAS(G12C) that was three orders of magnitude weaker than that observed for KRAS(G12C), suggesting that the MRTX849 scaffold preferentially engages the K-isoform of RAS, which is consistent with our NMR spectroscopy results.

We next sought to accurately assess the contribution to SII-P engagement from noncovalent ligand–protein interactions. Because of the potential differences in the steric and electrostatic environments for the SII-P among the RAS variants, we synthesized derivatives of MRTX849 lacking the covalent acrylamide warhead and positioning groups with varied steric and electronic properties proximal to residue 12 (**9–14**, Fig. 5a), and we evaluated these compounds with the BRET target engagement assay (Fig. 5b, Supplementary Table 1 and Supplementary Fig. 11a). For most RAS variants, the saturated amide and sulfonamide derivatives (**9–14**) demonstrated comparable rank order vulnerability with those of MRTX849 and MRTX1257. Among non-G12C variants, WT KRAS remained the most vulnerable of all RAS isoforms to reversible engagement, followed closely by hotspot KRAS mutants G13D, Q61H and Q61L. KRAS(G12V), KRAS(Q61R) and WT HRAS showed weak to no engagement across all saturated amides, similar to the results observed with MRTX849/1257. Engagement of KRAS(G12C) by most of the saturated amide derivatives was impaired in the absence of the covalent mechanism, with the exception of the sulfonamide (**14**), which demonstrated modest affinity (3.0  $\mu\text{M}$ , Fig. 4c).

Within the saturated amide series, **9** and **10** containing acetamide and propionamide moieties, respectively, were generally well tolerated. The methylsulfonamide derivative **14** was also well tolerated, in most cases demonstrating comparable engagement potency with the **9** and **10**, except in the case of KRAS(G12C) where it was found to be moderately selective compared with other derivatives. The electron-deficient trifluoroacetamide **13** demonstrated right-shifted moderate to weak potency in all cases compared with **9** and **10**, suggesting the importance of polar interactions with the amide carbonyl<sup>34</sup>. The bulky *iso*-butyramide **11** demonstrated the weakest engagement potency among all of the amides across all RAS isoforms. Compound **11** also caused an increase in the BRET signal for some RAS variants (Supplementary Fig. 11a), which was probably related to cytotoxicity (Supplementary Fig. 11b,c). Posing a ring constraint to the branched isopropyl group (that is the cyclopropyl carboxamide presented in **12**) improved the potency compared with **11**, but still demonstrated only moderate to weak potency in most cases. These saturated amides elicited cytotoxic effects in a RAS-independent cell line at similar concentrations (Supplementary Fig. 11b,c); however, our BRET system still permitted the direct measurement of SII-P engagement without prohibitive interference from off-target toxicity.

**MRTX-EX185 engages KRAS mutants and drives antiproliferation.** Because our NMR results demonstrated the unique capability of MRTX-EX185 to bind to both the GDP state and the GTP state of KRAS(G12D) in a cell-free system, we next evaluated this compound



**Fig. 4 | SII-P binders engage KRAS WT and G12 hotspot mutants.**

**a–c**, BRET target engagement profiles of MRTX849 (**4**) (**a**), MRTX1257 (**b**) and noncovalent methylsulfonamide derivative **14** (**c**). BRET is normalized relative to a saturating (20  $\mu\text{M}$ ) dose of BI-2852, as marked. **a, b**, Data are representative of three independent experiments, and each data point is the mean of three or four technical replicates  $\pm$  s.d. ( $n = 3$ ). **c**, Each data point is the mean of three independent experiments  $\pm$  s.e.m. ( $n = 3$ ).

in a cellular setting using our BRET assay. Potent target engagement (Figs. 5b and 6a and Supplementary Table 1;  $\text{IC}_{50}$  value of 90 nM) was observed for MRTX-EX185 with KRAS(G12D), greatly surpassing the engagement potency of the GDP-state-specific MRTX849 derivatives. Although MRTX-EX185 and MRTX849 have some similar structural features, it is unknown whether both molecules engage KRAS in a similar pose within the SII-P. To provide support for engagement of MRTX-EX185 within the KRAS SII-P, we also assayed engagement of KRAS(Y96D), which contains a previously reported mutation conferring resistance to described SII-P inhibitors including MRTX849 (ref. <sup>11</sup>) (Supplementary Fig. 12a). KRAS(Y96D) engagement was not observed with MRTX849, **10** or

MRTX-EX185 by the BRET-based assay. This finding, in conjunction with the finding that all of the MRTX chemotypes in this study show weak to no binding to HRAS variants (in which residue 95 is a glutamine), is consistent with binding to the SII-P in a similar pose.

MRTX-EX185 was also evaluated for inhibition of KRAS(G12D):effector interactions in cells using a NanoBiT protein–protein interaction assay. MRTX-EX185 demonstrated time- and dose-dependent inhibition of the KRAS(G12D):CRAF(RBD) interaction (Supplementary Fig. 12b), providing support for functional disruption of MAPK signaling. The protracted inhibition of CRAF-RBD interactions may be due to the need for overexpression of the RBD, which would be expected to stabilize KRAS–GTP. Thus, evaluation of KRAS(G12D):CRAF interactions with endogenous proteins may be warranted to more accurately query the kinetics of pathway inhibition. p-ERK and cell viability analysis in SW-1990 cells confirmed that engagement with MRTX-EX185 translated into inhibition of mitogenic signaling and an antiproliferative effect in a G12D-driven lineage (Fig. 6b,c), with antiproliferative potency (70 nM) in close agreement with the BRET readout. Unlike the MRTX849 derivatives, nonspecific cytotoxicity did not confound the antiproliferative results, because MRTX-EX185 did not inhibit proliferation in a panel of control cell lines (Supplementary Fig. 12c). Taken together, these results along with the NMR findings indicate that GTP-state compatibility may support the superior SII-P engagement for KRAS(G12D) in cells. We therefore attempted to extend the utility of MRTX-EX185 to additional KRAS hotspot mutants. MRTX-EX185 engaged numerous KRAS Q61, G12 and G13 mutant proteins (Figs. 5b and 6a, Supplementary Table 1 and Supplementary Fig. 12d). Notably, MRTX-EX185 engaged KRAS(G12V) in cells, which is the most GTP-biased G12 allele described. Although the potency against individual mutants may require tailored chemical optimization, and engagement of WT KRAS may constrain the therapeutic window, our observation that a SII-P ligand can engage several GTP hydrolysis-deficient KRAS mutants signifies exciting opportunities to drug these KRAS mutants through this pocket.


## Discussion

Here we report subfamily-wide engagement of KRAS hotspot mutants with the preclinical inhibitor MRTX849 and structurally related molecules. This presents evidence of intracellular SII-P vulnerability across the prevalent oncogenic KRAS mutants including KRAS(G12D). To characterize target engagement across RAS species, we combined *in vitro* and intracellular biophysical approaches. NMR spectroscopy provided a defined system to observe reversible, noncovalent binding and to determine the impact of nucleotide status on KRAS vulnerability. However, cell-free methods are incapable of simulating the intracellular architecture where target engagement would naturally occur. To query engagement in cells, we developed a SI/II-P BRET probe that was competent to detect a variety of intracellular engagement mechanisms including ligands selective for either SI/II-P or SII-P. Mutually exclusive binding between the BRET probe and the SII-P ligands enabled a systematic evaluation of SII-P engagement across KRAS hotspot mutants. This mutual exclusivity is consistent with the dynamic nature of RAS effector occupancy in cells. It is probable that RAS occupancy in cells is conformationally selective, and on the basis of its small size, RAS may disfavor co-occupancy of multiple ligands or effector proteins. The BRET method reported here conditionally measures engagement at membrane-localized RAS complexes in cells. Target engagement results with known SII-P covalent inhibitors matched both engagement and MAPK inhibition within endogenous G12C driven lineages, supporting the accuracy of the engineered BRET method.

Expanding beyond inhibition of KRAS(G12C), the BRET system enabled us to observe engagement of WT KRAS and of the majority of KRAS hotspot mutants including G12D. As measured in the BRET system, the rank order vulnerability of KRAS hotspot mutants







**Fig. 6 | Characterization of engagement of KRAS with MRTX-EX185.**

**a**, BRET target engagement profiles for MRTX-EX185 (**6**) at KRAS(G12D) and KRAS(G12V). BRET is normalized relative to a saturating (20  $\mu$ M) dose of BI-2852 (**2**), as marked. Data are means of three independent experiments  $\pm$  s.e.m. ( $n=3$ ). **b**, EX185-driven antiproliferation (CellTiter-Glo) is observed in SW-1990 (KRAS(G12D)) but not in HEK293 (KRAS-independent) cells. Data are the means  $\pm$  s.e.m. of three independent experiments, each performed with at least three technical replicates ( $n=3$ ). **c**, EX185 inhibits p-ERK. Data are means  $\pm$  s.e.m. of three independent experiments ( $n=3$ ).

independent of target function may serve to characterize the broadest variety of engagement mechanisms and inhibitor chemotypes. Accordingly, the BRET target engagement method should serve as a complement to other functional assays that detect effector interactions in cells<sup>18</sup>. The BRET-based and NMR assays reported in this work provide a reliable workflow to rapidly profile direct target engagement across a variety of RAS hotspot mutants, which should be broadly enabling for SII-P inhibitor discovery. Similarly, these assays may also become important tools to assess KRAS secondarily mutations that are already emerging in clinical settings<sup>11,37,38</sup>.

These capabilities should aid in the evaluation and optimization of new and improved medicines for RAS-driven cancers and prevalent RASopathies.

### Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41589-022-00985-w>.

Received: 14 October 2021; Accepted: 28 January 2022;  
Published online: 21 March 2022

### References

- Moore, A. R., Rosenberg, S. C., McCormick, F. & Malek, S. RAS-targeted therapies: is the undruggable drugged? *Nat. Rev. Drug Discov.* **19**, 533–552 (2020).
- Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. *Nature* **503**, 548–551 (2013).
- Ostrem, J. M. L. & Shokat, K. M. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. *Nat. Rev. Drug Discov.* **15**, 771–785 (2016).
- Molina-Arcas, M., Samani, A. & Downward, J. Drugging the undruggable: advances on RAS targeting in cancer. *Genes* **12**, 899 (2021).
- Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature* **575**, 217–223 (2019).
- Lanman, B. A. et al. Discovery of a covalent inhibitor of KRAS<sup>G12C</sup> (AMG 510) for the treatment of solid tumors. *J. Med. Chem.* **63**, 52–65 (2020).
- Fell, J. B. et al. Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer. *J. Med. Chem.* **63**, 6679–6693 (2020).
- Janes, M. R. et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. *Cell* **172**, 578–589.e517 (2018).
- Patricelli, M. P. et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. *Cancer Discov.* **6**, 316–329 (2016).
- Lito, P., Solomon, M., Li, L.-S., Hansen, R. & Rosen, N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. *Science* **351**, 604–608 (2016).
- Tanaka, N. et al. Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. *Cancer Discov.* **11**, 1913–1922 (2021).
- Hunter, J. C. et al. Biochemical and structural analysis of common cancer-associated KRAS mutations. *Mol. Cancer Res.* **13**, 1325–1335 (2015).
- Zhang, Z. et al. GTP-state-selective cyclic peptide ligands of K-Ras(G12D) block its interaction with Raf. *ACS Cent. Sci.* **6**, 1753–1761 (2020).
- Niida, A. et al. Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging. *Bioorg. Med. Chem. Lett.* **27**, 2757–2761 (2017).
- Sakamoto, K. et al. K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology. *Biochem. Biophys. Res. Commun.* **484**, 605–611 (2017).
- Sogabe, S. et al. Crystal structure of a human K-Ras G12D mutant in complex with GDP and the cyclic inhibitory peptide KRpep-2d. *ACS Med. Chem. Lett.* **8**, 732–736 (2017).
- Teng, K. W. et al. Selective and noncovalent targeting of RAS mutants for inhibition and degradation. *Nat. Commun.* **12**, 2656 (2021).
- Durrant, D. E. et al. Development of a high-throughput NanoBRET screening platform to identify modulators of the RAS/RAF interaction. *Mol. Cancer Ther.* **20**, 1743–1754 (2021).
- Robers, M. B. et al. Target engagement and drug residence time can be observed in living cells with BRET. *Nat. Commun.* **6**, 10091 (2015).
- Wells, C. I. et al. Quantifying CDK inhibitor selectivity in live cells. *Nat. Commun.* **11**, 2743 (2020).
- Dixon, A. S. et al. NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. *ACS Chem. Biol.* **11**, 400–408 (2016).
- Crew, A. P. et al. Preparation of bifunctional compounds as modulators of proteolysis useful for treating cancer. Patent WO2019195609A2 (2019).
- Kawai, Y. et al. Preparation of 5,8-dihydropyrido[3,4-d]pyrimidine derivatives having inhibitory activity against KRAS G12D mutation and oral antitumor agents. Patent WO2021107160A1 (2021).
- Kawai, Y. et al. Synthesis of fused pyrimidine compounds having inhibitory activity against KRAS G12D mutation. Patent WO2021106231A1 (2021).

25. Wang, X. et al. 4-(3,8-Diazabicyclo[3.2.1]octan-3-yl)pyrido[4,3-d]pyrimidines as KRas G12D inhibitors and their preparation. Patent WO2021041671A1 (2021).
26. Lim, S. et al. Exquisitely specific anti-KRAS biodegraders inform on the cellular prevalence of nucleotide-loaded states. *ACS Cent. Sci.* **7**, 274–291 (2021).
27. Kessler, D. et al. Drugging an undruggable pocket on KRAS. *Proc. Natl Acad. Sci. USA* **116**, 15823–15829 (2019).
28. Abankwa, D., Gorfe, A. A. & Hancock, J. F. Ras nanoclusters: molecular structure and assembly. *Semin. Cell Dev. Biol.* **18**, 599–607 (2007).
29. Janosi, L., Li, Z., Hancock, J. F. & Gorfe, A. A. Organization, dynamics, and segregation of Ras nanoclusters in membrane domains. *Proc. Natl Acad. Sci. USA* **109**, 8097–8102 (2012).
30. Nan, X. et al. Ras-GTP dimers activate the mitogen-activated protein kinase (MAPK) pathway. *Proc. Natl Acad. Sci. USA* **112**, 7996–8001 (2015).
31. Philips, M. R. & Der, C. J. Seeing is believing: Ras dimers observed in live cells. *Proc. Natl Acad. Sci. USA* **112**, 9793–9794 (2015).
32. Li, Y. C. et al. Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders. *Proc. Natl Acad. Sci. USA* **117**, 12121–12130 (2020).
33. Tran, T. H. et al. The small molecule BI-2852 induces a nonfunctional dimer of KRAS. *Proc. Natl Acad. Sci. USA* **117**, 3363–3364 (2020).
34. Hansen, R. et al. The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors. *Nat. Struct. Mol. Biol.* **25**, 454–462 (2018).
35. Smith, M. J., Neel, B. G. & Ikura, M. NMR-based functional profiling of RASopathies and oncogenic RAS mutations. *Proc. Natl Acad. Sci. USA* **110**, 4574–4579 (2013).
36. Zhao, Q. et al. Real-time in-cell NMR reveals the intracellular modulation of GTP-bound levels of RAS. *Cell Rep.* **32**, 108074 (2020).
37. Awad, M. M. et al. Acquired resistance to KRASG12C inhibition in cancer. *N. Engl. J. Med.* **384**, 2382–2393 (2021).
38. Koga, T. et al. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments. *J. Thorac. Oncol.* **16**, 1321–1332 (2021).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.  
© The Author(s) 2022

## Methods

**Cell transfections and BRET measurements.** HEK293 cells (ATCC), HeLa Cells (ATCC), A375 cells (ATCC), HCT-116 cells (ATCC), NCI-H358 cells (ATCC), NCI-H647 cells (ATCC), MIA PaCa-2 Cells (ATCC) and SW-1990 cells (ATCC) were cultured in DMEM (Gibco) + 10% FBS (Seradigm), with incubation in a humidified, 37°C/5% CO<sub>2</sub> incubator. H1975 cells (ATCC) were cultured in RPMI 1640 (Gibco) + 10% FBS, with incubation in a humidified, 37°C/5% CO<sub>2</sub> incubator.

For RAS cellular BRET measurements, a luciferase donor signal was produced at multimeric RAS using the NanoBiT approach. Amino-terminal (N-terminal) large BiT (LgBiT) or small BiT (SmBiT) RAS fusions were encoded in pNB3K and pNB4K (respectively) expression vectors (Promega), including flexible 15-residue linkers (GSSGGGGSSGGSSG) between the tag and each RAS isoform. All KRAS open reading frames (ORFs) were based upon KRAS4B (UniProt P01116-2) and all HRAS ORFs were based upon UniProt isoform 1 (P01112-1). All RAS ORFs were full-length unless otherwise noted. HEK293 cells were transfected with SmBiT-RAS and LgBiT-RAS fusion constructs using FuGENE HD (Promega) according to the manufacturer's protocol. Briefly, SmBiT-RAS and LgBiT-RAS constructs were diluted together into Transfection Carrier DNA (Promega) at a mass ratio of 1:1.8 in Opti-MEM (Gibco), after which FuGENE HD was added at a ratio of 1:3 (µg of DNA: µl of FuGENE HD). For example, for a 1-ml size transfection complex, 1 µg each of the SmBiT-RAS and LgBiT-RAS DNAs were combined with 8 µg of Transfection Carrier DNA in 1 ml of Opti-MEM. One part (vol) of FuGENE HD complexes thus formed were combined with 20 parts (vol) of HEK293 cells suspended at a density of 2 × 10<sup>5</sup> per ml in Opti-MEM containing 1% (v/v) FBS, followed by incubation in a humidified, 37°C/5% CO<sub>2</sub> incubator for 18–24 h. The total concentrations for each plasmid were 5 ng per well for each RAS plasmid, and the total concentration of DNA was 50 ng per well. Following transfection, cells were washed with PBS solution, harvested by trypsinization and resuspended in Opti-MEM containing 1% (v/v) FBS. BRET assays were performed in white, 96-well non-binding surface plates (Corning) at a density of 2 × 10<sup>4</sup> cells per well. All chemical inhibitors were prepared as concentrated stock solutions in DMSO (Sigma-Aldrich) and diluted in Opti-MEM (unless otherwise noted) to prepare working stocks. Cells were equilibrated with the RAS BRET probe and test compound before BRET measurements, with an equilibration time of 2 h unless otherwise noted. RAS BRET probe was prepared first at a stock concentration of 100× in DMSO, after which the 100× stock was diluted to a working concentration of 20× in BRET probe dilution buffer (12.5 mM HEPES, 31.25% PEG-400, pH 7.5). For RAS BRET probe dose response measurements, the RAS BRET probe was added to the cells in an eight-point, two-fold dilution series starting at a final concentration of 2 µM. For target engagement analysis, the RAS BRET probe was added to the cells at a final concentration of 1 µM. To measure BRET with the RAS BRET probe, NanoBRET Target Engagement substrate (Promega) was added according to the manufacturer's recommended protocol, and filtered luminescence was measured on a GloMax Discover luminometer equipped with 450 nm BP filter (donor) and 600 nm LP filter (acceptor), using 0.5 s integration time. Unlike the full-length NanoLuc protein, the signal of which can be quenched in extracellular environments using an impermeable inhibitor of NanoLuc, the NanoBiT luciferase in its current form is not amenable to extracellular quenching using the same approach. Raw BRET ratios were calculated by dividing the acceptor counts by the donor counts. Milli-BRET units (mBU) were calculated by multiplying the raw BRET values by 1000. When normalized BRET was used, mBRET values were normalized using equation (1);

$$\text{Normalized BRET (\%)} = [(A - C) / (B - C)] \times 100 \quad (1)$$

Where  $A$  = mBRET in the presence of test compound and BRET probe,  $B$  = mBRET in the presence of vehicle and BRET probe and  $C$  = mBRET in the presence of a saturating 20-µM dose of BI-2852. Apparent BRET probe affinity values (half-maximum effective concentration (EC<sub>50</sub>)) were determined using the sigmoidal dose response (variable slope) equation available in GraphPad Prism (equation 2);

$$Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / \left( 1 + 10^{(\log EC_{50} - X) \times \text{HillSlope}} \right) \quad (2)$$

In some cases, the RAS BRET probe was not saturable up to the solubility limit of the BRET probe, so the EC<sub>50</sub> value of the BRET probe is reported as >1 µM. For determination of test compound potency, competitive displacement data were plotted with GraphPad Prism software and data were fit to equation (2) to determine the IC<sub>50</sub> value.

To measure the impact of full-length CRAF coexpression of target engagement assay behavior, experiments were performed as described above, except that DNA encoding untagged full-length CRAF (UniProt P04049-1) was substituted for the Transfection Carrier DNA.

To measure the interaction of KRAS NanoBiT dimers with CRAF-CRD-RBD-HaloTag, cells were transfected as described above, except that Transfection Carrier DNA was replaced with CRAF-CRD-RBD (residues 51–133, UniProt P04049-1)-HaloTag plasmid and cells were treated with 4% FBS overnight. During incubation with test compound (2 h for BI-2852 or 6 h for MRTX849),

cells were treated with 1× NanoBRET-618 ligand and BRET was detected per the manufacturer's instructions.

To measure target engagement and luminescence for ABL1 kinase, the NanoBRET Target Engagement Intracellular Kinase Assay, K-4 (Promega) was used according to the manufacturer's instructions. Briefly, experiments were conducted as described above for the RAS target engagement assays, except that NanoLuc-ABL1 fusion DNA (Promega) was transfected with Transfection Carrier DNA (Promega) at a mass ratio of 1:9, tracer K-4 was used at a final concentration of 0.33 µM, and the extracellular NanoLuc inhibitor was included in the BRET detection step at a final concentration of 20 µM.

**Measurements of total LgBiT-RAS levels.** Total LgBiT expression level was determined in the presence of a saturating concentration (100 nM) of high-affinity HiBiT peptide (Peptide 2.0), 1× NanoBRET Target Engagement substrate and 50 mg ml<sup>-1</sup> digitonin (as a permeabilization agent). Unfiltered luminescence was measured using the Nano-Glo protocol on a GloMax Discover luminometer with a 0.3 s integration time.

**Bioluminescent Imaging of NanoBiT-KRAS fusions in live cells.** All imaging experiments were performed using the LV200 bioluminescence imaging system (Olympus) equipped with an ImagEM ×2 EM-CCD camera (Hamamatsu) and a ×40 oil, 1.4 NA objective. HEK293 cells and HeLa cells were transiently transfected as described above for the RAS cellular target engagement assays. Control plasmids encoding MAPK14 and HDAC-NanoLuc fusions were from Promega. Cells were plated onto Nunc Lab-Tek II eight-well chambered coverslips (ThermoFisher Scientific) coated with 0.1% gelatin in 200 µl of growth medium (DMEM + 10% FBS) at a density of 4 × 10<sup>5</sup> cells per well. After 24 h of incubation at 37°C, 100 µl of Nano-Glo Live Cell Reagent (Promega) was added. All images were acquired with CellSens software (Olympus) using an electron multiplying gain of 600 and an exposure time of 5 s. Each image was generated using an average projection of ten images. Generation of average projections and linear adjustments of dynamic range were performed using Image J image-processing software (Fiji package).

**Measurements of disruption for KRAS(G12D):CRAF(RBD) interactions in cells using NanoBiT.** For the KRAS(G12D):CRAF-RBD NanoBiT interaction assay, cytomegalovirus-based expression constructs were made encoding fusions of LgBiT to KRAS 4B (UniProt P01116-2) with the G12D mutation and SmBiT to residues 51–133 of CRAF (UniProt P04049-1, CRAF(RBD)). HEK293 cells (~4 × 10<sup>6</sup>) were transiently transfected in T75 flasks with plasmids encoding a LgBiT-KRAS(G12D) and SmBiT-CRAF(RBD). Plasmids were transfected at 500 ng per construct per flask together with 9 µg of Transfection Carrier DNA (Promega) at a 3:1 lipid:DNA ratio using FuGENE HD (10 ml total volume). Following expression for 24 h, cells were plated at 20,000 cells per well in Opti-MEM 1 (Thermo) containing 4% FBS and allowed to attach overnight. Serial dilutions of MRTX-EX185 were made in Opti-MEM 1 containing 4% FBS and 1× Vivazine substrate (Promega N2581) to generate 1× solutions containing varying concentrations of MRTX-EX185. Existing medium was removed by plate inversion and blotting, and 1× solutions were added to respective wells. Luminescence was measured every 5 min in a GloMax Discover luminometer at 37°C for 16 h using a 1 s integration time.

**Measurements of antiproliferative activity in cells.** Antiproliferative activity was measured as a decrease in cellular ATP levels using the CellTiter-Glo 2.0 assay (Promega) according to the manufacturer's protocols. HEK293 were seeded at 2,500 cells per well and all other cell lines were seeded at 5,000 cells per well. Clear monophasic behavior was fitted to equation (2) to interpolate the antiproliferative potency (IC<sub>50</sub>). To fit the biphasic antiproliferative behavior of MRTX849 in H358 and MIA PaCa-2 cells, the data were fit to a biphasic inhibitor model with variable Hill slope (equation 3) below

$$Y = \text{Bottom} + (\text{Top} - \text{Bottom}) \times \text{Frac} / \left( 1 + (\text{IC}_{50_{1X}})^{nH1} \right) + (\text{Top} - \text{Bottom}) \times (1 - \text{Frac}) / \left( 1 + (\text{IC}_{50_{2X}})^{nH2} \right) \quad (3)$$

**Inhibition of ERK phosphorylation.** Cellular ERK phosphorylation (Thr202/Tyr204) was quantified using a p-ERK (Thr202/Tyr204) cellular kit (Cisbio). SW-1990 cells (1 × 10<sup>6</sup> cells per ml, 50 µl per well) were plated in cell culture medium (DMEM (Gibco) + 10% FBS (Seradigm)) 12 h before the experiments. On the day of treatment, serially diluted 2× solutions were prepared in cell culture medium (9 + 1 points, 3:1 dilution starting from 60 µM, DMSO 0.6%). Cells in each well were treated with 2× small-molecule solutions (50 µl), after which they were incubated for 4 h at ambient temperature. Media were removed by aspiration. Cells were lysed with 50 µl of supplemented lysis buffer 1× (Cisbio) for 30 min at ambient temperature. Lysates were homogenized and transferred (16 µl) to a low-volume 384-well detection plate (Corning 4513). Premixed p-ERK antibody solutions (4 µl, Advanced p-ERK1/2 d2 Ab 20× (19×) + Advanced p-ERK1/2 Eu Cryptate Ab 20× (19×) + detection buffer; Cisbio) were added to each well of the plates. The mixtures were incubated at ambient temperature for 4 h before reading on a TECAN plate reader using the TR FRET mode with 60-µs lag time and 500-µs

integration time. The ratio of the acceptor and donor emission signals for each individual well was calculated by

$$\text{TR FRET ratio} = [\text{Signal } 665 \text{ nm}] / [\text{Signal } 620 \text{ nm}] \times 10,000$$

Total ERK data were acquired via the same procedure using the Total ERK cellular kit (Cisbio) on the same cell lysates. For each marker (p-ERK or total-ERK), the TR FRET ratio was normalized to the respective DMSO control. The ratio of p-ERK over total-ERK was calculated and fit to equation (2) above.

**Induction of ERK phosphorylation by expression of KRAS constructs.** The impact of expressing untagged or NanoBit-tagged KRAS variants on ERK phosphorylation was evaluated in HEK293 cells overexpressing an ERK1 substrate protein using AlphaLISA SureFire Ultra p-ERK1/2 (Thr202/Tyr204) and AlphaLISA SureFire Total ERK 1/2 assays (PerkinElmer). The ERK1 substrate protein was NanoLuc-ERK1 (NanoLuc-MAPK3; Promega), which was coexpressed with the RAS vectors to create a uniform total-ERK level across various transfection conditions and minimize the potential impact of overexpressing KRAS on endogenous ERK levels. Moreover, the NanoLuc tag on the ERK1 substrate allowed total luminescence to be used as an independent method to ensure uniform expression across samples. HEK293 cells were transfected as described above for cellular RAS target engagement assays, except that the KRAS constructs, NanoLuc-ERK1 and Transfection Carrier DNA were combined at a mass ratio of 2:1:7 or as indicated in the figures. Cells were plated directly into white 96-well tissue culture-treated assay plates (Corning) at  $2 \times 10^5$  cells per ml (100  $\mu$ l total volume) and allowed to express overnight.

For p-ERK and total-ERK measurements, the medium was aspirated from the assay wells, after which 62  $\mu$ l of AlphaLISA lysis buffer was added to the cells and the plates were agitated for 10 min at 350 r.p.m. Cell lysates thus prepared were then analyzed using the AlphaLISA SureFire Ultra assays above according to the manufacturer's instructions. Fluorescence emission measurements at 615 nm were recorded on a BMG CLARIOstar instrument using the AlphaLISA protocol. Raw fluorescence values from p-ERK measurements were normalized to the raw fluorescence values from the total-ERK measurements from the same lysate samples to produce the p-ERK/total-ERK ratio that was used for comparison. The p-ERK or total-ERK positive control lysates provided with the AlphaLISA SureFire Ultra kits were diluted 1:1 with lysis buffer before analysis.

Total luminescence was measured in the NanoLuc-ERK1 expressing cell samples as described above for cellular RAS target engagement measurements, except that the Nano-Glo protocol (unfiltered luminescence) was used on the GloMax Discover instrument.

**Preparation of U-<sup>15</sup>N Ras proteins.** The plasmids for bacterial expression of HRAS 1–166 (WT; His-TEV-N; pProEx; ampicillin resistance) and KRAS 1–169 (WT, G12C and G12D; His-TEV-N; pJ411; kanamycin resistance) have been previously published<sup>2</sup>. BL21(DE3) competent cells were transformed with 1–2 ng of plasmid, and cultures were grown at 37 °C in M9 minimal media containing 1 g L<sup>-1</sup> of <sup>15</sup>N ammonium chloride (99%; Cambridge Isotope Laboratories) and the appropriate antibiotic (0.1 mg ml<sup>-1</sup> of carbenicillin or 0.1 mM kanamycin). Protein expression was induced after cooling the cultures to 18 °C ( $A_{600} = 0.4–0.6$ ) by adding 1.0 mM IPTG, and the flasks were shaken at 200 r.p.m. overnight. Procedures for lysis and purification were followed as previously published<sup>2</sup>. Nucleotide exchange from GDP to GPPNHP (Jena Biosciences) was performed before the final gel-filtration purification and according to a published procedure comprising EDTA-mediated exchange, desalting and cleavage of residual GDP with an alkaline phosphatase (CIP or Quick CIP; New England Biolabs)<sup>239–41</sup>. Final gel-filtration purification was performed on a Superdex 75 column (GE) with storage buffer. Proteins were concentrated to 0.5–1 mM (Amicon Ultra-4, 10k MWCO, EMD), concentrations were determined by UV absorbance ( $\epsilon = 13,410 \text{ M}^{-1}\text{cm}^{-1}$  for HRAS 1–166 and  $11,920 \text{ M}^{-1}\text{cm}^{-1}$  for KRAS 1–169), and aliquots were flash frozen with liquid N<sub>2</sub> and stored at –80 °C.

Storage buffer: 40 mM HEPES, 150 mM NaCl, 4 mM MgCl<sub>2</sub>, 5% glycerol, 7% D<sub>2</sub>O. Titrated to pH 7.4 with NaOH.

**Preparation of <sup>15</sup>N-labeled KRAS(G12C)–MRTX849.** A 4-ml 0.10 mM sample of U-<sup>15</sup>N KRAS(G12C)–GDP 1–169 ( $M_r = 19,579$ ) was reserved before the final gel-filtration purification step. The concentration was determined by a bicinchoninic acid assay (Pierce, ThermoFisher Scientific) relative to a BSA standard. A solution of MRTX849 (120  $\mu$ l, 10 mM in DMSO, 3.0 eq.) was added, and the mixture was rotated at ambient temperature for 15 min, then concentrated (Amicon Ultra-4, 10k MWCO, EMD) and purified by gel filtration (SD75, GE) as described above. The purified protein was analyzed by LC/MS to ensure complete conversion to the 1:1 protein–ligand adduct ( $M_r = 20,182$ ) and the concentration determined by a BCA assay (Pierce, ThermoFisher Scientific).

**<sup>1</sup>H–<sup>15</sup>N HSQC NMR sample preparation and acquisition.** General procedure: a 0.030- $\mu$ mol aliquot of U-<sup>15</sup>N protein in storage buffer was diluted to 255  $\mu$ l with HSQC NMR sample buffer on ice. Sodium trimethylsilylpropanesulfonate (DSS) (15  $\mu$ l, 20 mM in buffer) and the small-molecule ligand (30  $\mu$ l, 2.0 mM in dms-*d*<sub>6</sub>) were added, the sample was mixed by vortex, and the resulting

solution was transferred to a 5-mm D<sub>2</sub>O-matched Shigemi NMR tube (BMS-3). The final concentration of protein and ligand were 100 and 200  $\mu$ M, respectively. One-dimensional (1D) <sup>1</sup>H (ZGESGP) and two-dimensional (2D) <sup>1</sup>H–<sup>15</sup>N fast HSQC (FHSQCCF3GPPH, ns=8, tdf1=256, GARP decoupling) spectra were recorded on an 800 MHz Bruker Avance spectrometer at 298 K. For any case in which strong CSPs were observed, a second sample containing the same protein–ligand combination at 100 and 30  $\mu$ M, respectively was also prepared, and spectra were acquired under the same conditions. For the mixed samples containing both nucleotide states, the scan number was doubled (ns=16) to improve the signal-to-noise ratio. Some spectra were also acquired with 0, 5 and 10% dms-*d*<sub>6</sub> and/or with minor adjustments to pH and temperature for comparison to previously published assignments.

HSQC NMR buffer: 40 mM HEPES, 150 mM NaCl, 4 mM MgCl<sub>2</sub>, 7% D<sub>2</sub>O. Titrated to pH 7.4 with NaOH.

**<sup>1</sup>H–<sup>15</sup>N–<sup>1</sup>H NOESY-HSQC NMR sample preparation and acquisition.** A 0.150- $\mu$ mol sample of U-<sup>15</sup>N KRAS(G12C)–GDP–MRTX849 protein in storage buffer was diluted to 400  $\mu$ l with NOESY NMR buffer on ice. The buffer was exchanged to the NOESY NMR buffer with a desalting column (5 ml HiTrap Desalting, Cytiva and AKTA FPLC, GE). The protein-containing fractions were combined (1.5 ml), concentrated to 0.3 ml (10k MWCO Amicon Ultra-4, EMD), transferred to a 5-mm Shigemi NMR tube (BMS-3) and gently sparged with Ar before sealing with parafilm (final concentration ~0.5 mM). 1D <sup>1</sup>H (ZGESGP), 2D <sup>1</sup>H–<sup>15</sup>N fast HSQC (FHSQCCF3GPPH, ns=8, tdf1=256, GARP decoupling), and three-dimensional (3D) <sup>1</sup>H–<sup>15</sup>N–<sup>1</sup>H NOESY-HSQC (NOESYHSQCF3GPWG3D, ns=16, tdf1=128, tdf2=40, GARP decoupling, 120 ms mixing time) NMR spectra were recorded on an 800 MHz Bruker Avance spectrometer at 298 K. A second 2D HSQC spectrum was acquired after the 3D NOESY-HSQC experiment with identical parameters to confirm sample stability during the 28 h acquisition.

A 0.374- $\mu$ mol sample of U-<sup>15</sup>N KRAS(G12D)–GDP in protein buffer was diluted with NOESY NMR buffer, and the buffer was exchanged as described above. The concentration of the resulting 1.5-ml solution was determined to be  $0.20 \pm 0.03$  mM by a BCA assay (Pierce, ThermoFisher Scientific); and this solution was concentrated to 0.50 ml (0.60 mM). A 200- $\mu$ l aliquot (0.12  $\mu$ mol) of this solution was diluted to 294  $\mu$ l with the same buffer, and MRTX849 or EX185 (6  $\mu$ l, 20 mM in dms-*d*<sub>6</sub>) was added. The samples were prepared as described above, and the same series of spectra were acquired. The remainder of the protein solution (100  $\mu$ l, 0.060  $\mu$ mol) was diluted to 294  $\mu$ l with the same buffer, dms-*d*<sub>6</sub> (6  $\mu$ l) was added, and 1D <sup>1</sup>H and 2D fast <sup>1</sup>H–<sup>15</sup>N HSQC spectra were acquired from this sample for comparison.

NOESY NMR buffer: 20 mM sodium phosphate, 140 mM NaCl, 15 mM MgCl<sub>2</sub>, 10 mM EDTA, 3 mM NaN<sub>3</sub>, 1 mM GDP, 1 mM DSS, 10% D<sub>2</sub>O. Titrated to pH 7.4 with NaOH.

**NMR data analysis.** Spectra were analyzed with Bruker Topspin 4.0, CCPNMR Analysis v.3 (ref. <sup>42</sup>) and/or MestReNova v14. <sup>1</sup>H chemical shifts were referenced to 1 mM DSS at 0 ppm; <sup>15</sup>N chemical shifts were referenced indirectly with  $\Xi = 0.101329118$ . The spectra images were created with CCPNMR Analysis v.3. Full spectra of each protein–ligand combination (red) superimposed with the dms-*d*<sub>6</sub> control (blue) are shown in Supplementary Note 1. Well-resolved peaks of the unbound proteins were assigned by comparison with data imported from the BMRB. For the protein–ligand combinations identified as strongly binding, many peaks of the protein–ligand complexes exhibited large CSPs, and no chemical exchange between bound and unbound proteins was observed; therefore, very few peaks in the HSQC spectra of these protein–ligand complexes could be confidently assigned based solely on this data. 3D NOESY-HSQC data were analyzed with CCPNMR Analysis v.3. Sequential backbone NH <sup>1</sup>H and <sup>15</sup>N shifts were identified by mutual NOESY crosspeaks. Segments belonging to the P-loop (13–20), SI (35–38), SII (73–77) and  $\alpha$ 4 (128–135) were assigned from this data, and CSPs were calculated by comparison of this data with data from spectra of the unbound protein acquired under the same conditions.

BMRB data used for reference:

- HRAS–GDP 1–166: entry 18479 (ref. <sup>43</sup>).
- HRAS–GPPNHP 1–166: entry 17678 (ref. <sup>43</sup>).
- KRAS–GDP 1–169: entry 27720 (ref. <sup>44</sup>).
- KRAS(G12C)–GDP 1–169: entry 27646 (ref. <sup>44</sup>).
- KRAS(G12D)–GDP 1–169: entry 27719 (ref. <sup>44</sup>).

**Quantification and statistical analysis.** Data from multiple independent experiments (*n*) are presented as mean values  $\pm$  s.e.m. and data involving technical replicates are presented as mean  $\pm$  s.d. as indicated in the figure captions. The number of experimental or technical replicates for each experiment is also described in each individual figure caption. Apparent affinity values were determined using the sigmoidal dose–response (variable slope) equation available in GraphPad Prism (v.8).

**Reporting Summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

### Data availability

Source data are provided with this paper. The authors declare that the data supporting the findings of this study are available within the article, the accompanying Source Data, the Supplementary Information and the Supplementary Data. Additional information, resources and reagents will be made available upon reasonable request; requests should be directed to and will be fulfilled by the lead contact M.B.R.

### References

- Ahmadian, M. R. et al. Guanosine triphosphatase stimulation of oncogenic Ras mutants. *Proc. Natl Acad. Sci. USA* **96**, 7065–7070 (1999).
- John, J. et al. Kinetics of interaction of nucleotides with nucleotide-free H-ras p21. *Biochemistry* **29**, 6058–6065 (1990).
- Maurer, T. et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. *Proc. Natl Acad. Sci. USA* **109**, 5299–5304 (2012).
- Skinner, S. P. et al. CcpNmr AnalysisAssign: a flexible platform for integrated NMR analysis. *J. Biomol. NMR* **66**, 111–124 (2016).
- O'Connor, C. & Kovrigin, E. L. Assignments of backbone  $^1\text{H}$ ,  $^{13}\text{C}$  and  $^{15}\text{N}$  resonances in H-Ras (1–166) complexed with GppNHp at physiological pH. *Biomol. NMR Assign.* **6**, 91–93 (2012).
- Pálffy, G., Vida, I. & Perczel, A.  $^1\text{H}$ ,  $^{15}\text{N}$  backbone assignment and comparative analysis of the wild type and G12C, G12D, G12V mutants of K-Ras bound to GDP at physiological pH. *Biomol. NMR Assign.* **14**, 1–7 (2020).

### Acknowledgements

D.M.P. is supported by a Ruth L. Kirschstein National Research Service Award from the National Cancer Institute of the National Institutes of Health (NIH; F32CA253966). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Q.Z. is the Connie and Bob Lurie Fellow of the Damon Runyon Cancer Research Foundation (DRG-2434-21). Z.Z. is a Damon Runyon Fellow supported by the Damon Runyon Cancer Research Foundation (DRG-2281-17). K.M.S. would like to acknowledge support from the NIH (5R01CA244550), the Mark Foundation for Cancer Research EXTOL, the Samuel Waxman Cancer Research Foundation and the Howard Hughes Medical Institute. We would also like to thank M. Kelly (University of California San Francisco) for his advice and assistance with NMR spectroscopy experiments. We are grateful to N. Murphy

for providing the CRAF-RBD/HaloTag plasmid, and to T. Machleidt and S. Knapp for helpful input on this manuscript.

### Author contributions

D.M.P. performed and analyzed the data from protein NMR spectroscopy experiments. J.A.W., J.D.V. and C.R.C. designed and synthesized the BRET probe. M.R.T. designed the RAS expression constructs. M.B.R. and J.D.V. designed the in-cell RAS BRET assay system. C.A.Z. performed and analyzed the data from the BRET assays. Q.Z. synthesized the noncovalent SII-P inhibitors. J.D.V. and M.B.R. performed and analyzed the CellTiter-Glo antiproliferation experiments. B.F.B. and M.T.B. designed and performed the RAS–RAF interaction assay. Q.Z. and Z.Z. performed and analyzed the data from the ERK phosphorylation assays. K.M.S. and M.B.R. guided the study and supervised the research from their respective groups. J.D.V., D.M.P., Q.Z., Z.Z., K.M.S. and M.B.R. wrote the manuscript.

### Competing interests

J.D.V., J.A.W., C.A.Z., M.R.T., M.T.B., B.F.B., C.R.C. and M.B.R. are employees of Promega Corporation, which holds patents related to the NanoBRET Target Engagement method. K.M.S. is an inventor on patents owned by University of California San Francisco covering KRAS targeting small molecules licensed to Araxes and Erasca. K.M.S. has consulting agreements for the following companies, which involve monetary and/or stock compensation: Revolution Medicines, Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics, Erasca, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Mitokinin, Type6 Therapeutics, Venthera, Wellspring Biosciences (Araxes Pharma), Turning Point, Ikena, Initial Therapeutics and BioTheryX.

### Additional information

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41589-022-00985-w>.

**Correspondence and requests for materials** should be addressed to Matthew B. Robers or Kevan M. Shokat.

**Peer review information** *Nature Chemical Biology* thanks Ken Westover and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The authors declare that the data supporting the findings of this study are available within the article, the accompanying Source Data, the Supplementary Information, and the Supplementary Data. Additional information, resources, and reagents will be made available upon reasonable request; requests should be directed to and will be fulfilled by the Lead Contact Matthew B. Robers. [Matt.Robers@promega.com](mailto:Matt.Robers@promega.com)

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences  Behavioural & social sciences  Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

|                 |   |
|-----------------|---|
| Sample size     | No sample size calculation was performed. Sample sizes were chosen on the basis of prior studies in NMR and BRET/Luminescence experiments that showed significant effects with similar sample sizes.  |
| Data exclusions | No data were excluded from these analyses   |
| Replication     | Replicated experiments were successful and support the conclusions drawn in this report. In the case of inhibitor potency information, the data generated in this study were reproducible by 2-3 independent scientists. All data in main figures were reproduced by 2-3 independent scientists. Bioluminescence imaging was replicated in 2 independent experiments by the same scientist. The data in supplementary figures 3A, 5F, 9(a, b, and e), 10 (a-h), 11a, and 12 (a) were reproduced by 2 independent scientists in 2-3 independent experiments. Experiments in supplementary figures 3, 5(b,c,d,e, and g), 6(B-I), 7b, 8(b-e), 9 (c and d), 10 (i and j), 11(b and c), and 12 (b-d) were only performed once by single scientists. All attempts at replication were successful. |
| Randomization   | No formal randomization method was used in this study to avoid mislabeling during inhibitor testing.  |
| Blinding        | Blinding was not relevant to this study because no bias could be made by the subject or the tester in the experiments performed.  |

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

- |                                     |   |
|-------------------------------------|---|
| n/a                                 | Involved in the study                                     |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Antibodies                       |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Eukaryotic cell lines |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology and archaeology    |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Animals and other organisms      |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Human research participants      |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Clinical data                    |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Dual use research of concern     |

### Methods

- |                                     |   |
|-------------------------------------|---|
| n/a                                 | Involved in the study                           |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq               |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Flow cytometry         |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> MRI-based neuroimaging |

## Eukaryotic cell lines

Policy information about [cell lines](#)

|   |  |
|---|--|
| Cell line source(s)   | HEK-293 cells (ATCC, CAT# CRL-1573), HeLa cells (ATCC, CAT# CCL-2), A-375 cells (ATCC, CAT# CRL-1619), HCT-116 cells (ATCC, CAT# CCL-247), NCI-H358 cells (ATCC, CAT# CRL-5807), NCI-H647 cells (ATCC, CAT# CRL-5834), Mia PaCa-2 Cells (ATCC, CAT# CRL-1420), and SW-1990 cells (ATCC, CAT# CRL-2172) were cultured in DMEM (Gibco) + 10% FBS (Seradigm), with incubation in a humidified, 37°C/5% CO <sub>2</sub> incubator. H1975 cells (ATCC, CAT# CRL-5908) were cultured in RPMI 1640 (GIBCO) + 10% FBS, with incubation in a humidified, 37°C/5% CO <sub>2</sub> incubator. Cells were passed for at least two generations after cryorecovery before they were used for assays. |
| Authentication  | We did not perform cell line authentication.   |
| Mycoplasma contamination  | All cell lines were tested mycoplasma negative using MycoAlert™ Mycoplasma Detection Kit (Lonza).  |
| Commonly misidentified lines (See <a href="#">ICLAC</a> register) | HEK293 and HeLa cells were used in this study.   |